Vertex Pharmaceuticals (VRTX) Cash & Current Investments (2009 - 2026)

Vertex Pharmaceuticals' Cash & Current Investments history runs 18 years deep, the most recent figure standing at $7.2 billion for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 16.86% year-over-year to $7.2 billion in Q1 2026; TTM through Mar 2026 was $7.2 billion, a 16.86% increase from a year earlier, with the FY2025 full-year figure at $6.6 billion, up 8.05% from the prior year.
• Cash & Current Investments advanced to $7.2 billion in Q1 2026 per VRTX's latest filing, from $6.6 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $11.9 billion in Q3 2023 and bottomed at $5.8 billion in Q2 2024.
• The 5-year median for Cash & Current Investments is $8.2 billion (2022), against an average of $8.5 billion.
• Across the five-year window, Cash & Current Investments soared 43.24% in 2022 and sank 48.42% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $10.8 billion in 2022, then gained by 4.08% to $11.2 billion in 2023, then tumbled by 45.48% to $6.1 billion in 2024, then gained by 8.05% to $6.6 billion in 2025, then climbed by 9.66% to $7.2 billion in 2026.
• Per Business Quant, the three latest VRTX Cash & Current Investments figures stand at $7.2 billion (Q1 2026), $6.6 billion (Q4 2025), and $6.3 billion (Q3 2025).